Next Article in Journal
Immunotherapy with an HIV-DNA Vaccine in Children and Adults
Next Article in Special Issue
Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation
Previous Article in Journal / Special Issue
Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses
Article Menu

Export Article

Open AccessReview
Vaccines 2014, 2(3), 549-562;

Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification

Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China
Author to whom correspondence should be addressed.
Received: 25 March 2014 / Revised: 30 May 2014 / Accepted: 4 June 2014 / Published: 15 July 2014
(This article belongs to the Special Issue Peptide Vaccine)
Full-Text   |   PDF [885 KB, uploaded 17 July 2014]   |  


Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines. View Full-Text
Keywords: tumor; vaccine; multi-component; multivalency; nano-size tumor; vaccine; multi-component; multivalency; nano-size

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Huang, Z.-H.; Sun, Z.-Y.; Gao, Y.; Chen, P.-G.; Liu, Y.-F.; Chen, Y.-X.; Li, Y.-M. Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification. Vaccines 2014, 2, 549-562.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top